The effect of a new formulation of the gastric prokinetic agent cisapride on opioid-induced gastric stasis was investigated. Forty patients were randomly allocated to one of four therapies administered as premedication; group A, placebo suppositories only; group E, placebo suppositories and intramuscular morphine 10 mg; group C, rectal cisapride 30 mg and intramuscular morphine 10 mg and group D, rectal cisapride 60 mg and intramuscular morphine 10 mg. Gastric emptying was assessed from the small bowel absorption of paracetamol following oral absorption. The kinetics of the suppository formulation were determined from venous blood samples. Rectal cisapride in the two doses used did not prevent opioidinduced gastric stasis. This may reflect an inability of this formulation to produce adequate plasma concentrations.
Pulmonary aspiration due to inhalation of gastric contents is an important cause of anaesthetic morbidity and mortality.! Opioids, commonly given as part of premedication for elective and emergency procedures, inhibit gastric motility and subsequent emptying. 2 Agents which act on the gastrointestinal tract to promote activity, gastric prokinetic drugs, have been used in an attempt to abolish the unwanted gastrointestinal effects of opioids, while at the same time retaining the required analgesia, anxiolysis and sedation. Metoclopramide has a variable effect in antagonising the effects of opioids and the results from a recent study suggest that the effectiveness of metoclopramide may depend on the route of administration. 3 Cisapride, a substituted benzamide, has been developed as a gastrointestinal prokinetic agent. Cisapride has been reported to antagonise morphine-induced gastric stasis when given intramuscularly4 and was more effective than intramuscular metoclopramide on gastric motility when these two agents were compared. 5 Thus, the recent introduction of this agent to the Australian formulary has significant implications for both anaesthesia and intensive care in this country. 6 The parenteral formulation of cisapride was only available for clinical trials: however, a rectal suppository formulation of cisapride has now been prepared for clinical use. 4 The purpose of this investigation was to study both its effect on gastric emptying following morphine premedication and the rate of absorption of the rectal cisapride suppositories.
PATIENTS AND METHODS Approval for this study was obtained from the Flinders Medical Centre Drugs and Therapeutics Advisory Committee and the Committee on Clinical Investigation. Forty patients (male and female), aged 18-65, who were scheduled for elective surgery, gave their informed consent to participate. Patients who had acute or chronic gastrointestinal disease, renal or hepatic impairment, or were on medication that could alter gastric motility, or could possibly be pregnant were excluded from the study.
Patients were randomly allocated to receive, double blind, one of four therapies.
Group A patients were given two placebo suppositories. Group B patients were given two placebo suppositories plus morphine 10 mg IM. Group C patients were given one cisapride 30 mg suppository plus placebo suppository along with morphine 10 mg IM.
Group D patients were given two 30 mg cisapride suppositories plus morphine 10 mg IM. Following an overnight fast, a peripheral intravenous sampling cannula was inserted using local anaesthesia. The suppositories were then inserted and sixty minutes later morphine was administered IM using a 23 swg needle into the deltoid muscle of the nondominant arm. Soluble paracetamol (Withthrop Pharmaceuticals, Australia) 1.5 g was taken after being dissolved in 50 ml water, 80 minutes after the insertion of the suppositories. A blood sample (5 ml) was withdrawn before insertion of the suppositories and this was repeated at fifteen-minute intervals for the duration of the study (3.25 hours).
The rate of absorption of drugs is minimal in the stomach compared with the small intestine and therefore the rate of absorption following oral administration may be an indirect measurement of the rate of gastric emptying. Various 'marker' solutes have been used for this purpose including glucose, ethanol and paracetamol. We have chosen the measurement of paracetamol plasma concentration as the 'marker' drug in this study as it can provide an indirect assessment of gastric emptying which correlates well with direct quantitative methods. 7 The indices that can be used to detect differences in paracetamol absorption, and hence gastric emptying, are maximum concentration achieved (C ma ..), time to the maximum concentration (T ma.) and area under the paracetamol-time curve (AUC). Alterations in gastric motility can be inferred from changes in one or more of these indices. Plasma paracetamol estimation was carried out by a standard HPLC technique. 8 Indices measured in this study were T maX' C max and area under the plasmaconcentration time curve 0 to 40 minutes and 0 to 115 minutes, determined by the trapezoidal rule (AUC O • 40 and AUC O • 115 )' Plasma cisapride concentration, measured at fifteen-minute intervals for the duration of the study, was determined by HPLC using a modification of the method of Woestenborghs. 9 A single solvent back extraction into 0.005 M phosphoric acid was followed by ultraviolet detection at 309 nm. The maximum concentration of cisapride achieved (CisC max ) and the time to the maximum concentration of cisapride achieved (CisTmax) was compared between groups.
Finally, morphine concentration was measured at the time of paracetamol ingestion in order to ensure that differences in emptying rates were due to effects of the cisapride rather than widely different morphine levels. Morphine concentration was determined by HPLC with electrochemical detection. 10 
STATISTICAL ANALYSIS
Data from the four groups were compared by one factor analysis of variance. A priori contrasts were used to assess the effect of morphine (Group A vs Groups B, C and D), the effect of cisapride in preventing morphine-induced gastric stasis (Group B vs C and D) and dose-related effect of cisapride (linear trend over Groups B, C and D). A Pvalue of less than 0.05 was taken as being significant.
RESULTS
Demographic data are given for the four groups are given in Table 1 . There were no differences apparent between groups. (9) 76 (19) 168 (9) 67 (14) 167 (10) 
(IS)
170 (11) Operation Gynae (5) Orthopaedic (I) General (2) Urology (2) Gynae (6) Urology (4) Gynae (5) Orthopaedic (2) General (I) Urology (2) Gynae (6) Orthopaedic (I) General (2) One patient (Group C) had one episode of diarrhoea in the anaesthetic induction room. Mild nausea was encountered by another patient in Group C, but his resolved over the course of the study. Patient 38 (Group D) was withdrawn due to nausea and vomiting seventy minutes after the administration of the morphine. No serious adverse effects were attributable to cisapride administration.
Patients in Group A, who had received placebo suppositories, had higher AUC O _ 40 and AUCO-l15 than the groups who received morphine (B, C and D); the difference however was not significant. The placebo group (A) however was significantly different from the three groups that received the morphine (B, C and D) with respect to C max (P < 0.05). Borderline statistical significance was achieved when the T max was compared between groups A and B (0.05 < P < 0.06). All three groups which received morphine (B, C and D) had similar mean values for AUC0-40 , AUCO-l15 , Tmax and C max ( Table 2 ). There was no significant dose-related or non dose-related effect of cisapride on any of these parameters (P> 0.25).
Although the plasma concentration of cisapride at the time of paracetamol ingestion (t = 80 min) was different between the two groups that received cisapride (C and D), this became smaller as the study progressed and there was no difference between the groups at the termination of the sampling (Figure 1 ). Plasma morphine concentrations showed a wide range of values but were not different between groups B, C and D, (Table 3 ).
DISCUSSION
The group of patients who received morphine had a significantly reduced paracetamol absorption compared with those in whom the morphine was omitted. This would indicate that morphine reduces the rate of gastric emptying in this group of patients. The 30 and 60 mg cisapride suppositories used in this study failed to prevent the morphineinduced gastric stasis.
The maximum paracetamol concentration, C max , proved to be the kinetic factor showing the greatest difference between the groups and therefore was the most sensitive indicator of differences in gastric motility in this study. Although proven effective as a measure of gastric motility, this study revealed that there is great variability when trying to discriminate between groups. Other studies using similar numbers of patients have demonstrated differences with the other parameters, T max and AUC. This has important implications for future work in this area and emphasises the need for a method of evaluation of gastric motility which is more specific and has less variability than the paracetamol absorption method. Rowbotham 5 reported that cisapride, in a dose of Cisapride concentration, time to maximum concentration and morphine concentration Mean (SD).
10 mg intramuscularly, significantly reduced the effects of morphine on gastric emptying, whereas 4 mg intramuscularly had no effect: effective antagonism of the opioid-induced gastric stasis was seen when the plasma concentration was approximately 100 ng. ml-1. The rectal formulation used here did not achieve mean drug concentrations greater than 50 ng.ml-1, which corresponded to that seen with the clinically ineffective (4 mg) parenteral dose seen in that study. 4 It was noted that although initial plasma levels of cisapride did differ between the two groups, as time progressed there was no significant difference between the plasma levels achieved between the 30 mg (one suppository) and 60 mg (two suppositories) dose formulation. The mean plasma levels of morphine were demonstrated to be comparable amongst the three groups of patients that received this opioid. Any lack of effect of cisapride therefore was not related to widely different morphine levels at time of investigation. The bioavailability of this suppository (which is cyclodextrin-based) compared with tablet formulation has been reported to be approximately 40%, with an absolute bioavailability of about 25%.11 Bioavailability depends on the physiochemical properties of the drug e.g. solubility, particle size, pI<.", drug concentration and surface properties and its carrier base e.g. composition, fusion behaviour, surface tension and rheological behaviour (i.e. the ability of the suppository preparation to be solid enough to be easily inserted, whilst allowing rapid liquefaction and subsequent absorption following insertion into the rectum). 12 Athough the plasma concentrations of cisapride seen with the 30 mg formulation were comparable to those obtained in other studies with the 4 mg parenteral dose, there was no increase in concentration when two 30 mg suppositories were Anaesthesia and Intensive Care, Vol. 19, No. 3, August, 1991 administered simultaneously. This may indicate that absorption is the rate-limiting factor in achieving adequate concentration of cisapride.
An alternative to the oral route of administration is useful for any drug, 13 The rectal route has potential advantages in that it is independent of gastric emptying, unaffected by nausea and vomiting and reduces, though to a variable extent, the first pass effect. It may be useful for patients fasting before theatre and also for those postoperative patients who cannot tolerate oral intake. It may also be of value for patients in the intensive care unit who are on a ventilator and requiring sedation, and who do not tolerate an oral intake, The surface area of the rectum is much smaller than that of the small intestine (200 cm 2 v 2,000,000 cm 2 ), hence the effective area for uptake of the drug is markedly reduced. Other factors of importance relating to the uptake of a drug via the rectal route include the venous drainage of the rectum and the relative uptake by portal and systemic circulations, pH of the rectal fluid and the presence of faecal matter impairing absorption.
At this hospital opioids were found to be part of the premedication prescription in over 35% of patients presenting for surgery.14 Recent work has shown that when administered prophylactically, the amount of opioid needed to prevent postoperative pain was much less than that required to relieve pain once present. 15 This should lead to an increased use of opioids in routine premedication but may increase the potential for side-effects, especially gastrointestinal, to become more evident. A reliable prokinetic agent would be of value to counteract these unwanted effects. Moreover, this detrimental effect of opioids on gastrointestinal activity is frequently seen in the intensive care unit. Gastrointestinal stasis can lead to abdominal distention, impairment of enteral feeding, necessitating the institution of parenteral nutrition with all of its logistical, metabolic and financial consequences. Cisapride has been shown by other workers to have a useful action, but there appears to be a threshold concentration below which there is no useful effect. Further work is needed by anaesthetists to investigate the kinetics of different pharmaceutical preparations of the same dose of this drug administered by the rectal route as well as the effect of increasing the dose itself. Evaluation of cisapride administered as a component of premedication to reduce fasting gastric aspirate volumes is also warranted.
